newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

  • Aligos Therapeutics presented positive data from four sessions, including two oral presentations, at the HEP-DART 2025 Meeting held December 7–11, 2025, in Honolulu, Hawaii.
  • Phase 1 monotherapy data for pevifoscorvir sodium showed continued potential as a first-line therapy for chronic hepatitis B virus (HBV) suppression following 96 weeks of treatment.
  • Nonclinical data for ALG-055009 demonstrated synergistic weight loss when combined with incretin receptor agonists (SEMA or TIRZEP) in diet-induced obese mice.
  • Combination therapy of ALG-055009 with semaglutide resulted in a maximum 33% body weight loss, while combinations with low-dose or high-dose tirzepatide achieved maximum losses of 39% and 40% respectively.
  • The additional weight loss from adding ALG-055009 was attributed primarily to fat mass reduction without significant effects on lean mass or food consumption.
  • Poster presentations highlighted early-stage antisense oligonucleotide programs targeting both HBV and hepatitis delta virus (HDV).
  • Lawrence Blatt, Chairman, President, and CEO, stated that the data supports the potential of pevifoscorvir sodium for chronic HBV and ALG-055009 for future cardiometabolic combination regimens.